TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy, to reduce the frequency of surgeries for adults with recurrent respiratory papillomatosis. In the trial supporting approval, 27% of a 26-patient subgroup went 12 months without an excision; postmarketing trials must verify the treatment’s clinical benefit.
The FDA has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy, to reduce how often adults with recurrent respiratory papillomatosis (RRP) need surgery to remove airway growths. The decision offers a new treatment option for a rare disease that can require repeated operations, but the agency will require postmarketing trials to verify and describe the therapy’s clinical benefit.
The approval covers doruxapapogene ralaplasmid-lalikinogene sifuplasmid, sold as Voceryq. The FDA based its decision on RRP-001, an open-label phase I/II trial involving 32 patients who had undergone at least two surgeries in the year before entering the study. The trial assessed whether treatment could reduce the need for further surgical removal of papillomas.
Among 26 participants who had undergone at least three surgeries in the 12 months before treatment, 27% had a complete response, defined as needing no surgical excisions during 12 months of follow-up. That result applies to this subgroup and this measure; it does not mean that all treated patients avoided surgery or that the disease was cured. The study was open-label, and the supplied report does not give a comparison with an untreated or placebo group.
Voceryq contains two plasmids carrying genetic instructions for HPV proteins and interleukin 12. The treatment is intended to prompt patients’ healthy cells to produce those proteins and stimulate an immune response against cells infected with HPV types 6 and 11, which cause RRP. Treatment starts with surgical debulking of visible growths, followed by four intramuscular doses, each given three weeks apart. It is used with the CELLECTRA 5PSP delivery device.
FDA label warnings include muscle contractions, transient bleeding and vasovagal reactions. The most common adverse events reported in trials included injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness. The supplied report does not provide rates for these events or a detailed comparison of safety outcomes.
A New Option to Reduce Repeat Surgery
RRP causes papillomas to grow in the respiratory tract, particularly around the larynx. The growths can return after removal, so patients may undergo repeated surgical procedures. In severe cases, disease can spread through the respiratory tract and make breathing difficult. There is no cure, according to the source report, making the possibility of extending time between operations relevant to patients facing recurring treatment.
Surgery remains part of the Voceryq regimen: patients first have visible papillomas surgically removed before receiving the injections. The approval is for reducing the frequency of excisions, not replacing surgery in every case. The trial’s complete-response result indicates that some patients in a heavily operated subgroup required no excisions over the reported 12-month follow-up, while the available information does not establish how long that benefit lasts or how patients fare beyond that period.
The decision also adds to a small set of medical options for RRP. The FDA approved zopapogene imadenovec (Papzimeos) for the condition in 2025, described in the source report as the first approved medical therapy. Voceryq is identified as the first FDA-approved recombinant plasmid DNA-based immunotherapy. Those descriptions refer to different milestones; neither changes the need for further evidence on Voceryq’s benefit.
Products Worth Considering
Therabody SleepMask Blackout Eye Mask with Vibration
Oral-B iO Series 5 Rechargeable Electric Toothbrush with 3 Brush Heads and Travel Case, Black
Hyperice Hypervolt 3 Pro Percussion Massage Gun with Heated Head and Carry Case
As an affiliate, we earn on qualifying purchases.
RRP is associated with human papillomavirus, especially HPV types 6 and 11. The virus-related growths form in the airways and may recur after surgical removal. Because the disease can affect the larynx and, in severe cases, other parts of the respiratory tract, repeated operations carry risks as well as the burden of ongoing care.
Voceryq’s two plasmids contain coding for HPV proteins and interleukin 12. According to the source report, patients’ own healthy cells transcribe that coding, with the aim of stimulating immune attacks against HPV-infected cells. The treatment is administered after surgical debulking, so it is designed to accompany rather than immediately eliminate the initial need for an operation.
The FDA used an accelerated approval pathway for the decision. Under the reported terms, postmarketing trials are required to verify and describe the treatment’s clinical benefit. The approval announcement is therefore a regulatory milestone, while confirmation of benefit remains part of the agency’s follow-up process.
“The approval of Voceryq is an important step in improving the quality of life for RRP patients as every surgery carries the risk of laryngeal injury.”
— Simon Best, MD, Johns Hopkins University investigator, in a statement from Inovio Pharmaceuticals
Questions About Long-Term Benefit
The supplied report does not state how many patients in the full 32-person trial achieved a response, provide a direct comparison group, or describe the durability of benefit beyond the 12-month follow-up used to define complete response. It also does not give detailed rates for individual adverse events. These gaps limit what can be concluded from the summary about how well the treatment works across the broader RRP population or how its risks compare with other care.
The FDA requires postmarketing trials to verify and describe clinical benefit, but the report does not specify their design, enrollment, timetable or outcome measures. It is also unclear from the supplied information whether the agency has set a deadline for those studies or what regulatory action could follow their results.
Postmarketing Trials Will Test Benefit
Inovio Pharmaceuticals and the FDA will need to move forward with the required postmarketing trials to verify and describe Voceryq’s clinical benefit. Those studies are expected to add evidence beyond the phase I/II data supporting the accelerated approval. The source material does not provide a schedule for when results are due.
For patients and clinicians, the immediate treatment decision will depend on individual disease history, prior surgeries, potential adverse effects and discussion with a medical team. The approval allows use for the specified purpose of reducing excision frequency in adults with RRP, but the available report does not establish that patients can forgo surgery altogether or predict who is most likely to respond.
Key Questions
What did the FDA approve Voceryq to do?
The FDA granted accelerated approval for Voceryq to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. The approval does not describe it as a cure.
How many patients avoided surgery in the reported trial result?
Among 26 participants who had at least three surgeries in the year before treatment, 27% had no excisions during 12 months of follow-up. This result is for that subgroup and does not represent all 32 trial participants.
Does Voceryq eliminate the need for surgery?
Not necessarily. Treatment begins with surgical debulking of visible papillomas. The FDA-approved purpose is to reduce the frequency of later excisions, and the reported trial result does not show that every patient can avoid further surgery.
What side effects were reported?
Warnings include muscle contractions, transient bleeding and vasovagal reactions. Common trial adverse events listed in the report included injection-site reactions, headache, fatigue, hypertension, nausea and dizziness. The report does not give event rates.
What evidence is still required?
The FDA requires postmarketing trials to verify and describe the therapy’s clinical benefit. The supplied report does not state when those studies will be completed or when their results are expected.
Source: medpagetoday.com
